It was reported that Pfizer vaccine is more than 90% effective based on initial trials. Health experts welcomed the first interim data from a huge clinical test planned out well. However, mass rolls outs will not happen most likely this year.
German partner of Prizer, BioNTech said that they can roll out up to 50 million doses this year that is enough to cover 25 million people, thus producing up to 1.3 billion doses the next year. Experts said they wanted to see the full trial data, but the preliminary results looked encouraging.